Skip to content
CharitiesAidWelfare, Medical Health Aged Care

Leading Haematologist Professor John Seymour AM joins Leukaemia Foundation Board

Leukaemia Foundation 3 mins read

The Leukaemia Foundation is delighted to announce the appointment of Professor John Seymour to its Board, effective immediately.

With more than three decades of world-class leadership in haematology, research and patient care, Professor Seymour brings exceptional clinical and translational expertise to the Leukaemia Foundation Board – a major asset as we work to accelerate progress in blood cancer treatment, care and outcomes.

Professor Seymour is an internationally recognised haematologist who until recently led the Haematology Department at the Peter MacCallum Cancer Centre and Royal Melbourne Hospital.

Holding MBBS, FRACP, PhD and fellowship of the Australian Academy of Health and Medical Sciences (FAHMS), Professor Seymour continues to contribute as an Honorary Professorial Fellow at the University of Melbourne Department of Medicine.

He also co-chaired Australia’s National Blood Cancer Taskforce alongside Leukaemia Foundation CEO, Chris Tanti, and in 2015 was appointed a Member of the Order of Australia (AM) for his significant service to haematology.

Professor Seymour’s career reflects a deep commitment to patient-centred care, equitable access to world-class treatment, and translating research discoveries into real-world outcomes.

As a new member of the Leukaemia Foundation Board, Professor Seymour will play a pivotal role in helping guide the organisations strategic direction, whilst driving innovation, improving care and treatment standards and ensuring every Australian diagnosed with a blood cancer receives the best possible chance of survival and quality of life.

“We are deeply honoured to welcome Professor Seymour to the Leukaemia Foundation Board,” said Lucio Di Giallonardo, Leukaemia Foundation Board Chair.

“His expertise, clinical insight, research leadership and dedication to equitable care will be fundamental as we intensify our mission to transform blood cancer outcomes for all Australians.”

With blood cancer incidence and mortality on track to be the leading cancer in Australia by 2035, Professor Seymour’s appointment comes at a crucial time. 

“Blood cancer incidence is rising, and more Australians than ever are living with the disease and its long-term impacts,” said Mr Di Giallonardo.

“Strong leadership and insights are therefore critical to improve patient outcomes and close the gaps in access to the best treatment and care across Australia.”

With Professor Seymour’s guidance, the Leukaemia Foundation will be even better positioned to:

  • Accelerate translation of cutting-edge research into standard clinical practice;
  • Advocate for equitable access to advanced treatments and support services regardless of where people live;
  • Strengthen collaboration with clinicians, researchers and policymakers to improve care, early diagnosis, survivorship and long-term outcomes;
  • Ensure the Leukaemia Foundation remains at the forefront of innovation and patient-centred care for all blood cancer types.

“Professor Seymour’s seat at our Board strengthens our mission to ensure that no Australian faces blood cancer alone,” added Mr Di Giallonardo.

“We are determined to accelerate progress to save lives, improve care, and give every person affected by blood cancer in this country, hope and support when they need it most.”

For more information on Professor Seymour and the Leukaemia Foundation Board visit leukeamia.org.au.

-END-


About us:

About the Leukaemia Foundation: The Leukaemia Foundation stands with Australia to help cure and conquer blood cancer – with care. Together we are attacking every blood cancer, from every direction, in every way we can. We stand beside every Australian to be their voice and their someone-to-turn to, fighting to get them access to the best care. We also accelerate research that is delivering rapid advancements in blood cancer diagnosis and treatments. Plus, we provide services and support that empower people living with any blood cancer to live well after diagnosis. You can learn more about the Leukaemia Foundation and blood cancer at leukaemia.org.au


Contact details:

Please contact the Leukaemia Foundation media team at [email protected] or call 0473 154 079. 

More from this category

  • Medical Health Aged Care, Research Development
  • 13/01/2026
  • 14:06
Centre for Healthy Brain Ageing (CHeBA), UNSW Sydney

Simple tool predicts who is most at risk of dementia after stroke

A new international study led by researchers from UNSW Sydney’s Centre for Healthy Brain Ageing (CHeBA) has developed the first practical, five-year dementia risk…

  • Contains:
  • Business Company News, Medical Health Aged Care
  • 13/01/2026
  • 10:50
Nova Eye Medical (ASX:EYE)

Nova Eye Medical Reports Record Sales Result for December 2025 Quarter

HIGHLIGHTS Record December quarter with global sales of US$6.1 million, up 38% on pcp and 25% on the September 2025 quarter Global six-month sales…

  • Contains:
  • Finance Investment, Medical Health Aged Care
  • 13/01/2026
  • 10:09
Jane Morgan Management

NeuroScientific Biopharmaceuticals (ASX:NSB) Reports Clinical Response for StemSmart(TM) Treatment in Fistulising Crohn’s Disease Under Special Access Program

13 January 2026 – Perth, Australia | NeuroScientific Biopharmaceuticals Limited (ASX:NSB) has today announced a “Clinical Response” from patients treated with its patented StemSmart™ Mesenchymal Stem Cell (MSC) therapy under the Therapeutic Goods Administration’s (TGA) Special Access Scheme (SAS) for fistulising Crohn’s disease. Three of four patients treated in Cohort 1 of the Special Access Program demonstrated a successful “Clinical Response” following treatment with StemSmart™, with the fourth patient showing a partial response with further clinical assessment needed. A Clinical Response is defined as either closure of at least 50 per cent of fistula openings or a reduction in fistula…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.